Research and Development of
Therapeutic Apps in BrainTech/DTx

DTx by means of Open Innovation

MEDIASEEK has been working on BrainTech, which fuses neuroscience and IT, for a long time. We are developing our business in the DTx (digital therapeutics) field with the cooperation with our business partners, utilizing the neurofeedback technology that we have developed to regulate the brain's condition.
More specifically, our focus is on developing therapeutic apps in-house, focusing on diseases of the central nervous system such as chronic (lower back) pain, depression, and dementia, which are difficult to treat with drugs.

Our BrainTech/DTx Projects

At MEDIASEEK, we utilize BrainTech technology to research and develop therapeutic apps in the field of DTx.
We are partnered with various research institutes, pharmaceutical companies, and other institutions in collaborative projects of open innovation for proof-of-concept studies, regulatory approval, and sales of services.

Case Studies/Partners

Lower back pain is a major disease affecting Japanese people; according to the Ministry of Health, Labour and Welfare, most (about 85%) of patients with lower back pain who visit hospital outpatient clinics have nonspecific lower back pain with no identifiable cause.
Lower back pain is estimated to be the cause of 3 trillion yen in economic losses. The Pain Center at Chiba University Hospital will conduct a study to measure the effects of various treatments on patients with nonspecific chronic lower back pain with no identifiable cause, and the study will examine neurofeedback along with cognitive behavioral therapy and exercise therapy as potential treatment methods.
MEDIASEEK has provided technical cooperation in the form of an app and device for neurofeedback.

Dementia is one of the biggest social issues in Japan. The number of patients with dementia is expected to increase, with the Cabinet Office estimating that by 2030 there will be more than 7 million dementia patients in the country.
Since no cure for the root cause of dementia has yet been established, it is important to detect mild dementia, with mild symptoms, at an early stage.
For this early detection, MEDIASEEK has partnered with a manufacturer developing devices to research and develop a service that screens for mild dementia based on brain responses using BrainTech technology.

MEDIA SEEK INC.
〒108-0072 1-27-6,SHIROKANE, MINATO-KU, TOKYO, JAPAN
https://www.mediaseek.co.jp/
IR and Public Relations E-mail:press@mediaseek.co.jp

© 2018-2022MEDIASEEK,inc.